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Abstract
Background There are very few published data on the man-
agement of primary intrathoracic sarcoma, defined as sarco-
mas arising from the lung, pleura, andmediastinum, excluding
the chest wall. Therefore, the aim of this study was to evaluate
the outcome of patients with intrathoracic sarcoma treated at
an academic referral center over a 21-year period.
Methods A retrospective search was performed to identify
patients with intrathoracic sarcomas treated with surgical re-
section from January 1990 to November 2011 at the Univer-
sity of Washington Medical Center. Local control and overall
survival were analyzed in relation to the treatment received.
Results Thirty-five patients were identified. Hazard ratios for
local control, adjusted for tumor margin status, at 5 years were
0.74 (95 % CI [0.21, 2.58]) for the addition of chemotherapy
(CT) to surgery, 0.57 (95 % CI [0.15, 2.23]) with the addition
of (radiation therapy) RT, and 0.50 (95%CI [0.06, 4.03]) with
the addition of both CT and RT. At 7 years, the ratios for local
control were 0.69 (95 % CI [0.20, 2.36]) for CT added to
surgery, 0.58 (95 % CI [0.15, 2.27]) for RT, and 0.41 (95 %
CI [0.05, 3.33]) with the addition of both CT and RT. Hazard
ratios for overall survival, adjusted for sarcoma stage, at
5 years were 0.61 (95 % CI [0.16, 2.39]) for the addition of
CT to surgery, 1.03 (95 % CI [0.26, 4.08]) for the addition of
RT, and 0.54 (95%CI [0.11, 2.69]) for the addition of both CT
and RT. The 7-year hazard ratios for overall survival were 0.77
(95 % CI [0.23, 2.60]) for CT added to surgery, 0.99 (95 % CI
[0.25, 3.84]) for the addition of RT, and 0.42 (95 % CI [0.09,
2.05]) for both CT and RT with surgery. At 10 years, hazard
ratios for overall survival were 0.71 (95 % CI [0.21, 2.38]) for
added CT, 0.81 (95 % CI [0.21, 3.08]) for added RT, and 0.33
(95 % CI [0.07, 1.65]) for the addition of both CT and RT to
surgery.
Conclusions Our series is the largest published study of intra-
thoracic sarcoma which focuses on the survival benefit of
adding RT, chemotherapy or both to surgery in resectable
intrathoracic sarcoma. Our data suggest a potential benefit in
local control and survival from adjuvant therapy, with the
greatest benefit likely to come from combined CT and RT,
though none of the results achieved statistical significance.
As intrathoracic sarcomas are rare and histologically hetero-
geneous, larger collaborative studies are necessary to deter-
mine treatment efficacy and elucidate which histologic sub-
types are likely to benefit most from adjuvant therapy.
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Introduction
Sarcomas are malignancies that arise from cells of mesenchy-
mal origin, and consequently can be found in bone, muscle,
fat, cartilage and other connective tissue (http://cancer.gov/
cancertopics/cancerlibrary/what-is-cancer). They are rare,
accounting for less than 1 % of cancers in adults [1], and for
approximately 15–20 % of tumors in children [2]. In addition
these tumors are very heterogeneous with over 50 distinct
histologic subtypes with a wide anatomical distribution [2].
Consequently due to this heterogeneity, studies of systemic
therapy are very challenging. Historically they have been
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divided into soft tissue sarcomas, representing the majority of
cases, and malignant bone sarcomas, which make up a little
over 10 % [2].
Soft tissue sarcomas occur most commonly in the extrem-
ities, followed by the abdomen/pelvis and head and neck re-
gion [3]. In the USA, approximately 11,000 new cases are
reported each year, and close to 4000 attributed deaths occur
[4, 5]. They arise in all age groups, but are more commonwith
age (51.7 % >60 years, 27.6 % 40–60 years, and 20.7 % 20–
40 years), with a slight male predominance (1.1 male to 1.0
female) [6]. The etiology is usually unknown, though expo-
sures to radiation, chemicals, and longstanding lymphedema
have been suggested as risk factors [6]. Prognosis is most
strongly correlated with histological grade [7, 8], and to a
lesser extent with tumor size, positive surgical margins and
histological subtype [9, 10].
Primary intrathoracic sarcomas are rare soft tissue sarco-
mas of the lung, pleura, and mediastinum. The most common
Table 1 Patient characteristics, pathology, treatment, local control, and overall survival
Histology Treatment
modality










Angiosarcoma Surgery only Mediastinum III H Pos Female 25 3.3 4 AWD
Carcinosarcoma Surgery + CT Pleura/Lung III H Neg Male 51 13.6 13.6 DOD
Fibrosarcoma Surgery only Mediastinum IIb I Pos Female 53 19.9 88.3 DOD
Intimal sarcoma Surgery + CT Mediastinum IIa I Neg Male 55 60.6 60.6 AWD
Leiomyosarcoma Surgery + RT Mediastinum IIa I Neg Female 66 6.5 6.5 NED
Leiomyosarcoma Surgery + CT Mediastinum IIa H Neg Female 20 34 34 NED
Leiomyosarcoma Surgery + CT Mediastinum III H Pos Female 33 8.7 17.8 DOD
Leiomyosarcoma Surgery + CT Pleura/lung IIb I Neg Female 38 22 22 CODU
Leiomyosarcoma Surgery only Pleura/Lung III H Neg Female 72 53.4 53.4 NED
Liposarcoma Surgery only Mediastinum Ib L Pos Female 50 105.1 105.1 NED
Liposarcoma Surgery only Pleura/Lung IIb I Pos Female 43 17 17 NED
Liposarcoma Surgery + RT Pleura/Lung IIb I Pos Male 58 9 9 NED
MPNST Surgery + RT Pleura/Lung III H Pos Female 70 23.8 8.6 DOD
MPNST Surgery + RT Mediastinum Ib L Pos Female 51 8.6 204.6 AWD
Pleomorphic sarcoma Surgery + RT Mediastinum IIb I Pos Female 55 24 98 AWD
Solitary fibrous tumor Surgery only Pleura/Lung IIb H Pos Female 60 16.5 49 DOD
Solitary fibrous tumor Surgery + RT Pleura/Lung IIb I Neg Male 60 34 29.8 DOD
Solitary fibrous tumor Surgery only Mediastinum Ib L Pos Female 75 5.1 53 AWD
Solitary fibrous tumor Surgery only Pleura/Lung Ib L Pos Male 65 2 71.1 NED
Spindle cell sarcoma Surgery + RT Mediastinum III H Pos Male 44 71.1 31.8 DOD
Spindle cell sarcoma Surgery only Mediastinum III H Neg Male 51 31.8 80.6 DOD
Spindle cell sarcoma Surgery only Mediastinum III H Pos Male 36 74 0.3 DOD
Spindle cell sarcoma Surgery + RT Mediastinum Ib L Pos Female 54 0.1 45.5 AWD
Synovial sarcoma Surgery + CT Pleura/Lung III H Pos Male 43 45.5 163 NED
Synovial sarcoma Surgery + RT + CT Pleura/Lung III H Pos Female 47 163 11.6 CODU
Synovial sarcoma Surgery + CT Pleura/Lung IIb I Neg Male 38 11.6 66.6 AWD
Synovial sarcoma Surgery + CT Pleura/Lung IIb I Pos Female 32 37.2 19.9 DOD
Synovial sarcoma Surgery only Mediastinum IIb I Neg Male 21 3.5 21 DOD
Synovial sarcoma Surgery only Pleura/Lung III H Neg Male 47 16.3 1.6 DOD
Synovial sarcoma Surgery only Pleura/Lung III H Pos Female 49 1.6 78.5 DOD
Synovial sarcoma Surgery + RT + CT Pleura/Lung III H Neg Female 36 11 42.8 DOD
Synovial sarcoma Surgery + CT Pleura/Lung III H Neg Male 30 16 21.6 DOD
Synovial sarcoma Surgery only Pleura/Lung III H Pos Female 47 0 3.9 DOD
Synovial sarcoma Surgery + RT + CT Pleura/Lung III H Pos Male 32 12.8 12.8 DOD
Undifferentiated sarcoma Surgery only Pleura/Lung IIb I Pos Male 65 3.0 29.2 DOD
Abbreviations: AWD alive with disease,CODU cause of death unknown,CTchemotherapy,DOD dead of disease,H high, I intermediate, L low,MPNST
malignant peripheral nerve sheath tumor, NED alive with no evidence of disease, Neg negative, Pos positive, RT radiation therapy
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histological subtypes are angiosarcoma, leiomyosarcoma,
rhabdomyosarcoma, or a sarcomatoid variant of mesothelio-
ma [11]. The rarity of these tumors is reflected in the paucity
of literature specifically examining the efficacy of various
treatment modalities to guide clinical therapeutic approaches.
Frequently they are studied in combination with other soft
tissue sarcomas, and often are not assessed as a distinct subset
or not included at all [12–16]. They are commonly treated in a
similar manner to soft tissue sarcomas of the extremities, for
which more established guidelines exist [17].
Surgery is the primary treatment for localized intrathoracic
sarcomas. The role of radiation and chemotherapy, however,
is less established. Radiation therapy (RT) has been effective
as an adjuvant to surgery for soft tissue sarcomas of the ex-
tremity [16, 18] and has been shown to reduce local recur-
rences with either pre- or post-surgery treatments [19]. The
utility of chemotherapy (CT) is less clear, with no trial dem-
onstrating a clear survival benefit in resectable soft tissue sar-
coma [20–23]. Novel chemotherapeutic agents and combina-
tions are currently being investigated in the metastatic setting,
and may prove more efficacious [24]. Given the paucity of
published data on the management of primary intrathoracic
sarcoma, the purpose of this study was to assess the treatment
and outcome of patients with intrathoracic sarcoma treated at
the University of Washington, with particular attention to the




IRB approval was obtained to review medical charts for pa-
tients diagnosed with thoracic tumors at the University of
Washington Medical Center (UWMC) from January 1990 to
November 2011. Patients identified with intrathoracic sarco-
mas via pathology and imaging, who received surgical resec-
tion with or without adjuvant CT and RTwere included in the
study. Patients who received initial incomplete resections else-
where or who presented to our institution with locally recur-
rent disease were included, provided there was adequate in-
formation about their initial or primary tumor treatment, re-
spectively. Over the time period analyzed, patients were treat-
ed by an experienced multi-disciplinary team of physicians.
Informed consent for treatment was obtained from all patients
included in this study. Neoadjuvant/adjuvant chemotherapy
was administered based on individual patient presentation
with particular attention to histological subtype, tumor grade,
and tumor size.
Data collection
Resectable intrathoracic sarcoma was defined as a non-
metastatic (stage I, II or III) primary sarcoma arising in the
lung, pleura, or mediastinum. Each tumor was staged using
the AJCC 7th edition staging criteria [25]. Patient demograph-
ic data (sex, age at diagnosis); tumor specific data (date of
diagnosis, primary site, histology, size, grade, stage); margins
status (positive <1 cm, negative >1 cm); treatment modalities
received (neo-adjuvant radiation and/or chemotherapy or ad-
juvant radiation and/or chemotherapy); and outcomes (date of
last follow-up, date of death) were obtained by retrospective
Fig. 1 KM curves of overall survival and disease-free survival by 4-
category treatment
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chart analysis. The size of the tumor was defined as the max-
imum dimension (in centimeters) determined by CT at the
initial diagnosis. All tumor pathology was examined centrally
at the UWMC. Grade was classified according to the
FNCLCC system as either low, intermediate or high-grade
based on the number of mitoses, the amount of necrosis, and
cellular differentiation [26].
Statistical analysis
Patients were followed from date of diagnosis to death of the
patient, or end of the study period. Survival curves were plot-
ted using the Kaplan-Meier method [27]. Hazard ratios for 5-,
7-, and 10-year local control and overall survival were obtain-
ed using Cox regression models [28], adjusting for tumor sta-
tus (positive or negative) as a potential confounder in local
control, and sarcoma stage (low or high) in overall survival.
For the purposes of our analysis, Blow stage^ was defined as
any stage I or II sarcoma, while Bhigh stage^ was defined as
stage III. All analyses were conducted using R v.3.1.1 [29].
Local control was defined as the period from the date of first
treatment to the date of first recurrence of disease at the orig-
inal treatment site. Overall survival was defined as the interval
between the first treatment and most recent follow-up or death.
Results
Patient population characteristics
Thirty-five adults with non-metastatic intrathoracic sarcomas
treated at the University ofWashington between January 1990
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Table 2 Cox regression model
results for local control, adjusted
for margin status, by treatment
pattern. N=35
Patient treatment pattern Local control
5-year endpoint 7-year endpoint 10-year
endpoint





Surgery + RTa 0.57 (0.15, 2.23)
p=0.42
0.58 (0.15, 2.27) p=0.44 b













a Treatment with surgery only is the reference group (Ref)
b No events recorded beyond 7 years
Numbers presented are hazard ratios (with 95 % confidence interval), unadjusted p value
Table 3 Cox regression model
results for local control, adjusted
for sarcoma stage, by treatment
pattern. N=35
Patient treatment pattern Overall survival
5-year endpoint 7-year endpoint 10-year endpoint



























a Treatment with surgery only is the reference group (Ref)
Numbers presented are hazard ratios (with 95 % confidence interval), unadjusted p value
and November 2011 were identified. The patient population
ranged in age from 19 to 75 years at the date of diagnosis
(mean 47.4 years, median 49 years). There were 14 male pa-
tients (40 %) and 21 female patients (60 %). The site of tumor
origin was the mediastinum in 15 cases (42.9 %), and pleura/
lung in 20 cases (57.1 %). Tumor size was determined in 34
patients (97.1 %) and ranged in dimension from 2.7 cm to
33.5 cm (mean 12.3 cm). Common histological subtypes in-
cluded synovia l sarcoma (28.6 %), fol lowed by
leiomyosarcoma (14.3 %) and spindle cell sarcoma
(11.4 %). There were 5 tumors classified as low grade
(14.3 %), 12 as intermediate (34.3 %), and 18 tumors classi-
fied as high-grade (51.4 %). Five cases were categorized as
stage 1B, 3 as stage IIA, 11 as stage IIb, and 16 as stage III, per
the AJCC staging system. Patient characteristics, pathology,
treatment and survival status are listed in Table 1.
Treatment characteristics
Twelve patients (34.3 %) received initial treatment elsewhere,
prior to presenting at the UWMC. The previous treatments
were excisional biopsy or surgical resection in 8 out of 12
patients (66.7 %), and surgical resection with preoperative
chemotherapy in 4 patients (33.3 %). Of the 12 previously
treated patients, 1 patient (8.3 %) presented with residual dis-
ease, 2 patients (16.7 %) presented with tumor recurrence, and
9 patients (75.0 %) had an alternative presentation (e.g., un-
certain margin, negative margin). All 35 patients underwent
surgical resection for their tumors, and postoperative margin
status was recorded in all 35 cases. Of these patients, 2 (5.8%)
were left with gross disease, 20 patients (57.1 %) had a posi-
tive (<1 cm) margin and 13 (37.1 %) had a negative margin
(≥1 cm). Fifteen patients (42.9 %) received surgery only, nine
patients (25.7 %) received surgery and CT (either neo-
adjuvant and/or adjuvant chemotherapy), eight patients
(22.9 %) received surgery and RT (either neo-adjuvant and/
or adjuvant radiation therapy), and 3 patients (8.6 %) received
surgery and both CT and RT (either neo-adjuvant and/or ad-
juvant). The number of patients who received radiation was 11
Fig. 2 KM curves of overall and disease-free survival for addition of
radiation therapy
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Table 4 Cox model results for
local control by receipt of
radiation therapy, adjusted for
margin status. N=35
Patient treatment pattern Local control
5-year endpoint 7-year endpoint 10-year endpoint













a No events recorded beyond 7 years
Numbers presented are hazard ratios (with 95 % confidence interval)
(31.4 %) and the number of patients who received chemother-
apy was 12 (34.3%). Patients receiving chemotherapy primar-
i l y r ece ived i fo s f amide and doxo rub i c in . One
leiomyosarcoma patient also received gemcitabine and doce-
taxel and one of the synovial sarcoma patients received
carboplatin and paclitaxel. Overall the treatment groups were
similarly heterogeneous, with the exception of the three pa-
tients comprising the group that received all three treatment
Outcome
The mean patient follow-up time was 3.7 years. Disease re-
currence was observed in 21 patients (61.8 %). Of these 21
patients, 12 (57.1 %) experienced local recurrence, 6 (28.6 %)
experienced distant metastasis, and 3 (14.3 %) experienced
both local recurrence and metastasis. The most common sites
of metastases were the lung and bone (three patients each site)
followed by the brain (twp patients). Patient status as of last
follow-up revealed 9 patients (25.7 %) alive with no evidence
of disease, 6 patients (17.1 %) alive with disease, 18 patients
(51.4 %) had died of disease, and 2 patients (5.7 %) for whom
the cause of death was unknown.
Local control and overall survival
Survival results comparing four treatment groups
To compare the effects of different treatment patterns on over-
all and disease-free survival, the patient population was divid-
ed into four groups based on treatments received. Group 1
received surgery only, group 2 received surgery and CT, group
3 received surgery and RT, and group 4 received surgery and
both CTand RT. The survival results are displayed as Kaplan-
Meier curves in Fig. 1. Cox hazard ratio models comparing
these treatment groups for 5-, 7-, and 10-year local control are
detailed in Table 2. Hazard ratios for 5-, 7-, and 10-year over-
all survival are detailed in Table 3. Treatment with surgery
alone is the reference group.
Fig. 3 KM curves of overall and disease-free survival for addition of
chemotherapy
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modalities (surgery+chemo+radiation) who were all stage III,
high-grade synovial sarcoma cases.
Table 5 Cox model results for
overall survival by receipt of
radiation therapy, adjusted for
sarcoma stage. N=35
Patient Treatment Pattern Overall Survival
5-year endpoint 7-year endpoint 10-year endpoint

















Numbers presented are hazard ratios (with 95 % confidence interval)
Hazard ratios for local control at 5 years were as follows:
0.74 (95 % CI [0.21, 2.58]) for CT added to surgery, 0.57
(95 % CI [0.15, 2.23]) for RT, and 0.50 (95 % CI [0.06,
4.03]) with the addition of both CT and RT. At 7 years, the
ratios for local control were 0.69 (95%CI [0.20, 2.36]) for CT
added to surgery, 0.58 (95 % CI [0.15, 2.27]) for RT, and 0.41
(95 % CI [0.05, 3.33]) with the addition of both CT and RT.
10-year local control hazard ratios were not calculated, given
no events recorded after 7 years.
Hazard ratios for overall survival at 5 years were 0.61 (95%
CI [0.16, 2.39]) for the addition of CT to surgery, 1.03 (95 %
CI [0.26, 4.08]) for the addition of RT, and 0.54 (95 % CI
[0.11, 2.69]) for the addition of both CT and RT. The 7-year
hazard ratios for overall survival were 0.77 (95 % CI [0.23,
2.60]) for CT added to surgery, 0.99 (95 % CI [0.25, 3.84]) for
the addition of RT, and 0.42 (95%CI [0.09, 2.05]) for both CT
and RT with surgery. Hazard ratios for overall survival at
10 years were 0.71 (95 % CI [0.21, 2.38]) for CT added to
surgery, 0.81 (95 % CI [0.21, 3.08]) for added RT, and 0.33
(95 % CI [0.07, 1.65]) for the addition of both CT and RT.
Survival results comparing radiation vs. no radiation
To examine the effect of RT on local control and overall sur-
vival, the patient population was divided into two treatment
groups based on whether RTwas administered (RT vs no RT).
The survival results are displayed as Kaplan-Meier curves in
Fig. 2. Cox hazard ratio models comparing these treatment
groups for 5-, 7-, and 10-year local control and overall surviv-
al are detailed in Tables 4 and 5, respectively. The hazard
ratios for local control at 5- and 7-years were 0.60 (95 % CI
[0.18, 1.97]) and 0.59 (95 % CI [0.18, 1.91]), respectively,
compared to surgery only. There were no reported events be-
yond 7 years. The hazard ratio for overall survival at 5 years
was 0.90 (95%CI [0.31, 2.68]), 0.71 (95% CI [0.25, 2.04]) at
7 years, and 0.59 (95 % CI [0.20, 1.71]) at 10 years.
Survival results comparing chemotherapy vs. no
chemotherapy
To examine the effects of CT on local control and overall
survival, the patient population was likewise divided into
two groups (CT received vs. no CT). The survival results are
displayed as Kaplan-Meier curves in Fig. 3. Cox hazard ratio
models comparing these treatment groups for 5-, 7-, and 10-
year local control and 5-, 7-, and 10-year overall survival are
detailed in Tables 6 and 7. The hazard ratios for local control at
5 and 7 years were 0.78 (95 % CI [0.26, 2.35]) and 0.69 (95 %
CI [0.24, 2.01]). For mortality at 5 years, the hazard ratio was
0.58 (95 % CI [0.19, 1.74]), 0.61 (95 % CI [0.22, 1.70]) at
7 years, and 0.56 (95 % CI [0.20, 1.56]) at 10 years.
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Table 6 Cox model results for
local control by receipt of
chemotherapy, adjusted for
margin status. N=35
Patient treatment pattern Local control
5-year endpoint 7-year endpoint 10-year
endpoint












a No events recorded beyond 7 years
Numbers presented are hazard ratios (with 95 % confidence interval)
Table 7 Cox model results for
overall survival by receipt of
chemotherapy, adjusted for
sarcoma stage. N=35
Patient treatment pattern Overall survival
5-year endpoint 7-year endpoint 10-year endpoint

















Numbers presented are hazard ratios (with 95 % confidence interval)
Discussion
Intrathoracic sarcomas are a rare subgroup of soft tissue sar-
coma with poor prognosis and no established standard guide-
lines. Our study is the largest series of intrathoracic sarcoma
treated at a single institution focused on treatment and out-
comes of this rare set of neoplasms. This study highlights
the variability in histology and individualization of patient
treatment for this disease. Though surgery is the mainstay of
therapy for localized sarcomas, recent studies indicate that the
addition of (neo) adjuvant radiation and/or systemic therapy
can potentially improve outcomes [3, 17, 30]. Similar studies
examining thoracic wall (rather than primary pleural or pul-
monary) sarcomas found that chemotherapy, radiation, and
both in combination, each had a positive impact on local con-
trol and survival as adjunctive treatments [23, 31]. Our results,
which are the first to address prognostic variables and treat-
ment influence on local control and overall survival in intra-
thoracic sarcoma, are in agreement with these earlier findings
for sarcomas presenting in other locations and underscore the
prognostic power of high-grade disease in survival.
Notable limitations include lack of statistical power
due to limited sample size and variability in treatment
over the period of the study. However, our study is the
first to compare these treatment modalities for intrathorac-
ic sarcomas and attempt quantification of their effect on
local control and survival. Despite the limitations, this
study will serve as a benchmark for further larger studies
evaluating novel approaches in the management of intra-
thoracic sarcoma.
Due to the numerous histological subtypes and mani-
festations of intrathoracic sarcomas, a multi-disciplinary
approach to their management is essential, as coordination
between surgery, radiation, medical oncology, pathology
and radiology will facilitate clearer classification and
management strategies for these rare malignancies [17].
In order to improve the outcome of patients with rare
diseases, it is important that treatment is undertaken at
specialist centers [32]. Furthermore, international collab-
oration is required to assess the utility of novel therapies
in such malignancies as well as identifying the underlying
molecular drivers of these heterogeneous diseases.
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